BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/5/2014 11:43:00 AM | Browse: 1509 | Download: 1956
 |
Received |
|
2014-06-20 08:51 |
|
Peer-Review Started |
|
2014-06-20 20:52 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2014-07-17 15:47 |
|
Revised |
|
2014-07-28 16:00 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2014-09-05 16:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2014-09-05 17:18 |
|
Articles in Press |
|
2014-09-05 17:28 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2014-11-06 09:42 |
|
Publish the Manuscript Online |
|
2014-11-20 20:51 |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Topic Highlights |
| Article Title |
Risk of infections associated with biological treatment in inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Nynne Nyboe Andersen and Tine Jess |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nynne Nyboe Andersen, MD, Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen, Denmark. nyna@ssi.dk |
| Key Words |
Inflammatory bowel disease; Biological treatment; Tumor necrosis factor-α inhibitors; Risk; Infections; Ulcerative colitis; Crohn’s disease |
| Core Tip |
The use of tumor necrosis factor-α (TNF-α) inhibitors are increasing worldwide for the treatment of several chronic immune-mediated diseases as rheumatoid arthritis and inflammatory bowel disease (IBD). As the drugs are relatively new on the market, their long-term safety profile remains uncertain. In particular, a concern regarding an increased infections risk has been debated. In the current topic highlight, a brief overview of the current literature regarding the risk of infections in patients with IBD exposed to TNF-α inhibitors is outlined. |
| Publish Date |
2014-11-20 20:51 |
| Citation |
Andersen NN, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol 2014; 20(43): 16014-16019 |
| URL |
http://www.wjgnet.com/1007-9327/full/v20/i43/16014.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v20.i43.16014 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
